Misha Angrist, the Personal Genome Project and patient empowerment
Rade Drmanac, co-founder Complete Genomics
David Ewing Duncan, Experimental Man, Personal Health Manifesto
Jason Bobe, Personal Genome Project + Bioweathermaps
The Open Science Summit unites researchers, life science industry professionals, students, patients and other stakeholders to discuss the future of collaborative science and innovation.
This, the second year, features in-depth sessions on new models for drug discovery and clinical trials, personal genomics, the patent system, the future of scientific publications, and more.
Misha Angrist is Assistant Professor of the Practice at the Duke University Institute for Genome Sciences & Policy. He holds a PhD degree in Genetics from Case Western Reserve University, an MFA in Writing and Literature from the Bennington Writing Seminars, and was formerly a board-eligible genetic counselor. He has covered the biotechnology industry as market-research analyst and worked as an independent life sciences consultant, writer and editor.
In April 2007 he became the fourth subject in Harvard geneticist George Church's Personal Genome Project and in 2009 had his full genome sequenced at Duke. His book, Here is a Human Being: At the Dawn of Personal Genomics, will be published in the fall by Harper Collins.
Jason Bobe serves as the Executive Director of PersonalGenomes.org and Director of Community for the Personal Genome Project based out of George Church's lab at Harvard Medical School. The Personal Genome Project seeks to encourage the thoughtful development of personal genomics technology and practices by building frameworks for prototyping and evaluation at increasing scales.
Jason is co-founder of DIYbio.org, an organization that aims to help make biology a worthwhile pursuit for citizen scientists and amateur biologists. DIYbio is fast becoming the organizational hub for amateur biologists worldwide, uniting the movement's participants through its website, online forums, blog and local chapters.
He has also worked as a Business Development Consultant for OpenWetWare.org, as Director of Business Development at DNA Direct, and as an independent consultant. He has attended both the University of Colorado at Boulder and the Kelley School of Business at Indiana University. He is interested in how emerging biotechnologies and the web are redefining the relationships between scientific research communities, communities from the general public, and the network of actors in-between.
Radoje Drmanac Ph.D.
Dr. Radoje (Rade) Drmanac, chief scientific officer and co-founder of Complete Genomics since 2006, is a research scientist and inventor in the field of human genome sequencing including techniques such as DNA sequencing-by-hybridization (SBH), genomic microarrays and combinatorial probe ligation.
In 1994, he co-founded Hyseq (later Nuvelo) where, as chief scientific officer, he led the effort to discover and patent thousands of genes which formed the basis of Nuvelo's drug development pipeline. Prior to Hyseq, Rade was a group leader at Argonne National Labs from 1991 to 1994 as part of the Department of Energy's Human Genome Project. He completed his postdoctoral studies in 1990 in Hans Lehrach's group at the Imperial Cancer Research Fund in London. He earned his Ph.D. in molecular biology for the conception and pioneering development of SBH technology from Belgrade University, where he also received B.S. and M.S. degrees in molecular biology.
David Ewing Duncan
David Ewing Duncan is an award-winning, best-selling author of eight books published in 21 languages. He is a founder and co-curator of Arc Programs. David is a columnist for Newsweek, a correspondent for The Atlantic and the chief correspondent for NPR Talk’s Biotech Nation. David writes for The New York Times, Fortune, Wired, National Geographic, Discover and many other publications. He is a former commentator for NPR’s Morning Edition and a special correspondent and producer for ABC’s Nightline and 20/20, and correspondent for NOVA’s ScienceNow!. His latest book is When I’m 164: The new science of radical life extension, and what happens if it succeeds. He also wrote Experimental Man: What One Man’s Body Reveals about His Future, Your Health, and Our Toxic World (Wiley). He was the founder and director of the BioAgenda Institute, and the founding director of the Center of Life Science Policy at UC Berkeley. David is finishing his first novel, a biomedical thriller. David’s work has won numerous awards, including Magazine Story of the Year from the American Association for the Advancement of Science. His articles have twice been cited in nominations for National Magazine Awards, and his work has appeared twice in The Best American Science and Nature Writing. David lives in San Francisco and is a member of the SF Writer’s Grotto. His website is www.davidewingduncan.com.
U.S. research effort initiated in 1990 by the U.S. Department of Energy and the National Institutes of Health to analyze the DNA of human beings. The project, intended to be completed in 15 years, proposed to identify the chromosomal location of every human gene, to determine each gene's precise chemical structure in order to show its function in health and disease, and to determine the precise sequence of nucleotides of the entire set of genes (the genome). Another project was to address the ethical, legal, and social implications of the information obtained. The information gathered will be the basic reference for research in human biology and will provide fundamental insights into the genetic basis of human disease. The new technologies developed in the course of the project will be applicable in numerous biomedical fields. In 2000 the government and the private corporation Celera Genomics jointly announced that the project had been virtually completed, five years ahead of schedule.
all the genetic content contained within an organism. An organism's genome is made up of molecules of deoxyribonucleic acid (DNA) that form long strands that are tightly wound into chromosomes, which are found in the nucleus of eukaryotic organisms and in the cytoplasm of prokaryotic organisms. Chromosomes that are unique to certain organelles within a cell, such as mitochondria or chloroplasts, are also considered a part of an organism's genome. A genome includes all the coding regions (regions that are translated into molecules of protein) of DNA that form discrete genes, as well as all the noncoding stretches of DNA that are often found on the areas of chromosomes between genes. The sequence, structure, and chemical modifications of DNA not only provide the instructions needed to express the information held within the genome but also provide the genome with the capability to replicate, repair, package, and otherwise maintain itself. The human genome contains approximately 25,000 genes within its 3,000,000,000 base pairs of DNA, which form the 46 chromosomes found in a human cell. In contrast, Nanoarchaeum equitans, a parasitic prokaryote in the domain Archaea, has one of the smallest known genomes, consisting of 552 genes and 490,885 base pairs of DNA. The study of the structure, function, and inheritance of genomes is called genomics. Genomics is useful for identifying genes, determining gene function, and understanding the evolution of organisms.